STOCK TITAN

Adagene Inc. - $ADAG STOCK NEWS

Welcome to our dedicated page for Adagene news (Ticker: $ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adagene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adagene's position in the market.

Rhea-AI Summary
Adagene reports strong efficacy signal in MSS CRC phase 2 study for SAFEbody ADG126 in combination with pembrolizumab at 10 mg/kg every three weeks dosing regimen
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.89%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
conferences
Adagene Inc.

Nasdaq:ADAG

ADAG Rankings

ADAG Stock Data

115.25M
12.99M
4.19%
16.13%
0.03%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Suzhou

About ADAG

adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.